Reverse transcription polymerase chain reaction

“Replace bogus PCR tests to avoid unnecessary Coronavirus lockdowns,” Urges Milford Molecular Diagnostics Director Dr. Sin Hang Lee

Retrieved on: 
Monday, June 21, 2021

The current Coronavirus chaos is largely caused by phony PCR tests marketed as RT-qPCR assays, explained Dr.

Key Points: 
  • The current Coronavirus chaos is largely caused by phony PCR tests marketed as RT-qPCR assays, explained Dr.
  • Sin Hang Lee, director of Milford, Connecticut-based Milford Molecular Diagnostics ( www.dnalymetest.com ), in an article titled qPCR is not PCR, Just as a Straightjacket is not a Jacket - The Truth Revealed by SARS-CoV-2 False-Positive Test Results.
  • Now, even the general public is aware that RT-qPCR assays are generating numerable false-positive and false-negative test results, he said.
  • Both false-positive and false-negative RT-qPCR test results contributed to the current Coronavirus pandemic, said Dr. Lee.

Roche SARS-CoV-2 molecular test granted first FDA Emergency Use Authorization for PCR testing of both symptomatic and asymptomatic individuals at the point of care

Retrieved on: 
Friday, June 18, 2021

This singleplex test is the first real-time reverse transcriptase polymerase chain reaction (RT-PCR) test that can identify SARS-CoV-2 infection within 20 minutes.

Key Points: 
  • This singleplex test is the first real-time reverse transcriptase polymerase chain reaction (RT-PCR) test that can identify SARS-CoV-2 infection within 20 minutes.
  • The cobas SARS-CoV-2 test is the first RT-PCR test that screens within 20 minutes both asymptomatic and symptomatic persons, enabling quick, informed decisions at the point of care.
  • We are pleased that we can now provide a test to enable healthcare professionals to identify both asymptomatic and symptomatic infected individuals at the point of care," said Ian Parfrement, Head of Point of Care for Roche Diagnostics Solutions.
  • "Preventing further spread of the virus is crucial for public health and the continued safe reopening of our communities worldwide."

Roche SARS-CoV-2 molecular test granted first FDA Emergency Use Authorization for PCR testing of both symptomatic and asymptomatic individuals at the point of care

Retrieved on: 
Friday, June 18, 2021

This singleplex test is the first real-time reverse transcriptase polymerase chain reaction (RT-PCR) test that can identify SARS-CoV-2 infection within 20 minutes.

Key Points: 
  • This singleplex test is the first real-time reverse transcriptase polymerase chain reaction (RT-PCR) test that can identify SARS-CoV-2 infection within 20 minutes.
  • The cobas SARS-CoV-2 test is the first RT-PCR test that screens within 20 minutes both asymptomatic and symptomatic persons, enabling quick, informed decisions at the point of care.
  • We are pleased that we can now provide a test to enable healthcare professionals to identify both asymptomatic and symptomatic infected individuals at the point of care," said Ian Parfrement, Head of Point of Care for Roche Diagnostics Solutions.
  • "Preventing further spread of the virus is crucial for public health and the continued safe reopening of our communities worldwide."

ECDC supports EU/EEA Member States in rapid detection of SARS-CoV-2 variants

Retrieved on: 
Thursday, June 17, 2021

It is the key to identifying variants, as well as monitoring their spread in communities and populations.

Key Points: 
  • It is the key to identifying variants, as well as monitoring their spread in communities and populations.
  • The WGS services under the HERA Incubator include shipping of samples, laboratory sample preparation, sequencing and basic sequence analysis support.
  • In 2021, ECDC and the European Commission have made available EUR27000000 for outsourced WGS services.
  • National WGS and/or RT-PCR infrastructure support programme for EU/EEA public health authorities

    A sizeable and coordinated infrastructure investment in public health laboratories will allow Member States to develop a significant and cost-effective SARS-CoV-2 variant screening system.

Biocept Receives More Than 420,000 Samples During First Year of Offering COVID-19 Testing Service

Retrieved on: 
Tuesday, June 15, 2021

(Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces that it has received more than 420,000 samples for SARS-CoV-2 testing since launching this service in June 2020.

Key Points: 
  • (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces that it has received more than 420,000 samples for SARS-CoV-2 testing since launching this service in June 2020.
  • The samples are processed using Biocepts RT-PCR-based technology at its CLIA-certified, CAP-accredited, high-complexity molecular laboratory in San Diego.
  • We plan to further support our customers by offering a combination COVID-19 and seasonal influenza testing beginning in the third quarter of this year.
  • Biocept also is leveraging its molecular diagnostic capabilities to offer nationwide COVID-19 RT-PCR testing to support public health efforts during this unprecedented pandemic.

Tetracore, Inc. Introduces First USDA-Licensed Real-Time PCR Test for the Detection of Foot and Mouth Disease Virus in Bovine, Swine and Ovine

Retrieved on: 
Friday, June 11, 2021

The VetAlert FMDV RNAhigh-performance test kit was developed by Tetracore scientists and will be commercialized and sold by Tetracore.

Key Points: 
  • The VetAlert FMDV RNAhigh-performance test kit was developed by Tetracore scientists and will be commercialized and sold by Tetracore.
  • Nearly two decades ago, Tetracore validated and published a real-time RT-PCR assay for FMDV, as described by Callahan et al.
  • The primer and probe set from the publication became part of the OIE and USDA reference test methods.
  • Tetracore is a biotechnology company specializing in the development and manufacture of diagnostic devices and assays for the detection of infectious diseases.

Tetracore, Inc. Introduces First USDA-Licensed Real-Time PCR Test for the Detection of Foot and Mouth Disease Virus in Bovine, Swine and Ovine

Retrieved on: 
Friday, June 11, 2021

The VetAlert FMDV RNAhigh-performance test kit was developed by Tetracore scientists and will be commercialized and sold by Tetracore.

Key Points: 
  • The VetAlert FMDV RNAhigh-performance test kit was developed by Tetracore scientists and will be commercialized and sold by Tetracore.
  • Nearly two decades ago, Tetracore validated and published a real-time RT-PCR assay for FMDV, as described by Callahan et al.
  • The primer and probe set from the publication became part of the OIE and USDA reference test methods.
  • Tetracore is a Registered Trademark and VetAlert is a Trademark of Tetracore, Inc.
    View original content to download multimedia: http://www.prnewswire.com/news-releases/tetracore-inc-introduces-first-u...

Bruker Launches CE-IVD Quantitative Coronavirus Mid-Plex PCR Assay with Mutation Detection for Routine Variant Differentiation

Retrieved on: 
Monday, June 7, 2021

Bruker Corporation (Nasdaq: BRKR) today announced the launch of the FluoroType SARS-CoV-2 varID Q assay a quantitative LiquidArray mid-plex PCR panel.

Key Points: 
  • Bruker Corporation (Nasdaq: BRKR) today announced the launch of the FluoroType SARS-CoV-2 varID Q assay a quantitative LiquidArray mid-plex PCR panel.
  • The assay achieved a sensitivity of 98% and a specificity of 100% during its clinical performance evaluation study.
  • Sensitive and robust detection, mutation differentiation and quantification of viral load are all done simultaneously in a single PCR tube and a single assay run.
  • This permits efficient laboratory workflows without the need for a second PCR test, or for RNA sequencing for strain detection.

Biocept to Present at the LD Micro Virtual Invitational XI Conference on June 9, 2021

Retrieved on: 
Thursday, June 3, 2021

Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces that Michael Nall, President and CEO, will present at the LD Micro Virtual Invitational XI Conference on June 9, 2021 at 3:00 p.m. Eastern time (12:00 p.m. Pacific time).

Key Points: 
  • Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces that Michael Nall, President and CEO, will present at the LD Micro Virtual Invitational XI Conference on June 9, 2021 at 3:00 p.m. Eastern time (12:00 p.m. Pacific time).
  • Following the presentation, the webcast will be available on the Companys website for 90 days.
  • Biocept, Inc. develops and commercializes molecular diagnostic assays that provide physicians with clinically actionable information for treating and monitoring patients diagnosed with a variety of cancers.
  • Biocept also is leveraging its molecular diagnostic capabilities to offer nationwide COVID-19 RT-PCR testing to support public health efforts during this unprecedented pandemic.

Eurofins Launches a New Multiplex PCR Assay for Rapid Detection of the B.1.617 “India” SARS-CoV-2 Variant

Retrieved on: 
Thursday, June 3, 2021

Eurofins Technologies (Paris:ERF) announces the launch of its GSD NovaType III SARS-CoV-2 RT-PCR assay, developed for the rapid detection of SARS-CoV-2 Variants of Concern including B.1.617 (India), B.1.427/B.1.429 (California/USA), B.1.351 (South Africa) or P.1 (Brazil).

Key Points: 
  • Eurofins Technologies (Paris:ERF) announces the launch of its GSD NovaType III SARS-CoV-2 RT-PCR assay, developed for the rapid detection of SARS-CoV-2 Variants of Concern including B.1.617 (India), B.1.427/B.1.429 (California/USA), B.1.351 (South Africa) or P.1 (Brazil).
  • The assay facilitates the identification of the relevant mutations E484Q, E484K and L452R in one reaction combined with the simultaneous discrimination from the S gene E484 wildtype variant.
  • These mutations have been associated with reports of potential decreased efficacy of certain vaccines and an increase in the transmissibility of the virus.
  • Eurofins Technologies is committed to continue to rapidly adapt its product offering to the meet the evolving challenges of SARS-CoV-2.